Jason Zemansky

Stock Analyst at B of A Securities

(1.2)
# 1986
Out of 5,386 analysts
46
Total ratings
Success rate
Average return
14 Stocks
Name Action PT Current % Upside Ratings Updated
INSM Insmed
Maintains: Strong Buy
94 109
99.56 9.48% 10 Jun 11, 2025
KROS Keros Therapeutics
Downgrades: Neutral
32 18
13.48 33.53% 2 Jun 10, 2025
RCKT Rocket Pharmaceutica...
Maintains: Buy
32 9
2.52 257.14% 1 May 28, 2025
CYTK Cytokinetics
Maintains: Neutral
62 54
33.16 62.85% 4 Apr 15, 2025
TVTX Travere Therapeutics
Maintains: Strong Buy
29 31
14.76 110.03% 4 Apr 1, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
22 17
7.95 113.84% 5 Feb 19, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
36 29
5.67 411.46% 2 Nov 22, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
30 31
9.04 242.92% 3 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underperform
3 3
0.99 152.53% 5 Jun 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Underperform
391 23
n/a n/a 2 Dec 26, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Buy
230
n/a n/a 1 Jul 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Strong Buy
9 10
1.03 870.87% 4 May 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
450 162
n/a n/a 1 Feb 22, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Buy
145 155
n/a n/a 2 Dec 13, 2021